News
Sydney Biotech Minomic International Ltd Strikes New Arrangement to Make MiCheck® Prostate Test Available for Australians
Minomic International Ltd has taken a step forward to bring the MiCheck® Prostate test to Australians. MiCheck® Prostate detects aggressive prostate cancer overcoming the low accuracy of conventional screening tests, reducing unnecessary intervention such as painful...
Minomic International Ltd Celebrates US Lab Partnership at Ribbon Cutting Event
Minomic CEO Dr Brad Walsh and US Commercialisation Lead Megan Henken presented at its US lab partner 20/20 GeneSystems’ ribbon cutting event in Rockville, Maryland last week to celebrate the commencement of CLIAx’s operations. Last year 20/20 GeneSystems launched its...
Experts discussion on the unmet need for a new biomarker in biopsy decisions
Check out the new videos on our website minomic.com with two globally-recognised urologists Doctor Neal Shore and Professor Mark Emberton. Both experts discuss the unmet need for a new biomarker in biopsy decisions, while Professor Emberton considers how a test like...
Minomic Granted CLIA Certification Enabling Commercial Launch of MiCheck® Prostate in the US
Minomic International Limited is pleased to announce that its wholly owned subsidiary, Minomic Inc., has been granted a Clinical Laboratory Improvement Amendments (CLIA) certification, allowing its lab to officially open for business, in Gaithersburg, MD. The CLIA...
Minomic International Limited appoints US Lab Director
Minomic is pleased to announce the appointment of Dr Chih-Ling Zao as its US Laboratory Director. Chih-Ling is an American Board of Bioanalysis certified high-complexity Laboratory Director with over ten years’ extensive diagnostic laboratory experience in the...
Minomic takes MiCheck® Prostate to ASCO Genitourinary Cancers Symposium in San Francisco
Minomic International Limited recently attended the Genitourinary Cancers Symposium which was held in San Francisco and presented data from their latest study on the diagnostic test the company has developed to assist in the detection of aggressive prostate cancer....
Federal government funding to boost commercialisation of Minomic’s MiCheck® Prostate
SYDNEY: Minomic International Ltd. is pleased to announce that it is the beneficiary of a tranche of co-investment from the Advanced Manufacturing Growth Centre’s (AMGC) Commercialisation Fund and the Federal Government’s Modern Manufacturing Initiative. One of 24...
MiCheck® Prostate will be offered at CLIAx by 20/20 GeneSystems in the USA
Shared CLIA lab to help diagnostics start-ups, including Australian-based Minomic,more rapidly enter the U.S. market Rockville, MD, September 28, 2021 – 20/20 GeneSystems, Inc., (“20/20”), announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx),...
